Alexion to start Phase III study of blood disorder drug in Covid-19 respiratory disease

Alexion to start Phase III study of blood disorder drug in Covid-19 respiratory disease

Source: 
MedCity News
snippet: 

The biotech company said it would initiate a Phase III trial of Ultomiris in Covid-19-related pneumonia and acute respiratory distress syndrome. The announcement comes nearly a month after it said it was exploring the use of Soliris, an older and related drug.